ADMA Biologics (NASDAQ:ADMA) and Polarityte (NASDAQ:PTE) Financial Comparison

ADMA Biologics (NASDAQ:ADMA) and Polarityte (NASDAQ:PTE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Volatility and Risk

ADMA Biologics has a beta of 2.93, meaning that its stock price is 193% more volatile than the S&P 500. Comparatively, Polarityte has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.

Profitability

This table compares ADMA Biologics and Polarityte’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ADMA Biologics -370.27% -210.69% -63.98%
Polarityte -4,259.44% -99.38% -89.00%

Analyst Ratings

This is a breakdown of recent ratings for ADMA Biologics and Polarityte, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADMA Biologics 0 0 7 0 3.00
Polarityte 1 0 5 0 2.67

ADMA Biologics presently has a consensus target price of $11.17, indicating a potential upside of 188.54%. Polarityte has a consensus target price of $34.00, indicating a potential upside of 496.49%. Given Polarityte’s higher probable upside, analysts clearly believe Polarityte is more favorable than ADMA Biologics.

Valuation and Earnings

This table compares ADMA Biologics and Polarityte’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ADMA Biologics $16.99 million 13.12 -$65.74 million ($1.45) -2.67
Polarityte $1.56 million 90.32 -$65.44 million ($4.86) -1.17

Polarityte has lower revenue, but higher earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Polarityte, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

38.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 41.6% of Polarityte shares are held by institutional investors. 18.8% of ADMA Biologics shares are held by insiders. Comparatively, 43.3% of Polarityte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ADMA Biologics Company Profile

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also offers Nabi-HB, a hyperimmune globulin for the treatment of acute exposure; and Bivigam, an intravenous immune globulin for the treatment of primary humoral immunodeficiency. In addition, it operates source plasma collection facilities in Norcross, Marietta, and Kennesaw, Georgia. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Polarityte Company Profile

PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.